-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$10.80195.08% Upside
Sutro Biopharma, Inc. Frequently Asked Questions
-
What analysts cover Sutro Biopharma, Inc.?
Sutro Biopharma, Inc. has been rated by research analysts at Truist Financial, Deutsche Bank, Wedbush, Oppenheimer, Piper Sandler in the past 90 days.